Regression of subependymal giant cell astrocytoma with rapamycin in tuberous sclerosis complex.
The authors present a 21-year-old woman who has been receiving rapamycin for 5 months for bilateral subependymal giant cell astrocytomas. The patient was started at a dose of 0.2 mg/kg/day. Levels were maintained between 11 and 13 ng/mL. Magnetic resonance imaging of the brain 2(1/2) months after initiating rapamycin demonstrated a decrease in size of both astrocytomas (11 to 7.5 mm on the right and 8 to 5 mm on the left). Further studies are needed with prolonged observation to confirm these findings, determine the length of necessary treatment, and evaluate recurrence risk after discontinuation of rapamycin.
Koenig
Mary Kay
MK
Department of Pediatrics, Division of Child and Adolescent Neurology, The University of Texas Health Science Center, Houston, Texas, USA. mary.k.koenig@uth.tmc.edu
Butler
Ian J
IJ
Northrup
Hope
H
D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage*; D001921:Brain / Q000187:drug effects / Q000473:pathology; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D018315:Glioma, Subependymal / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D006801:Humans; D008279:Magnetic Resonance Imaging; D020123:Sirolimus / Q000008:administration & dosage*; D016896:Treatment Outcome; D014402:Tuberous Sclerosis / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D055815:Young Adult
D000903:Antibiotics, Antineoplastic; D020123:Sirolimus